U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H21N
Molecular Weight 275.3874
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CYCLOBENZAPRINE

SMILES

CN(C)CCC=C1C2=CC=CC=C2C=CC3=CC=CC=C13

InChI

InChIKey=JURKNVYFZMSNLP-UHFFFAOYSA-N
InChI=1S/C20H21N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-14H,7,15H2,1-2H3

HIDE SMILES / InChI
Molecular Formula C20H21N
Molecular Weight 275.3874
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/slideshow/flexeril-cyclobenzaprine-muscle-relaxants-1266 | http://www.rxlist.com/flexeril-drug.htm | https://www.ncbi.nlm.nih.gov/pubmed/26926618 | https://www.ncbi.nlm.nih.gov/pubmed/26668287

Cyclobenzaprine is a centrally-acting muscle relaxant which boosts levels of norepinephrine and binds to serotonin receptors in the brain to reduce spasm. Cytochromes P-450 3A4, 1A2, and, to a lesser extent, 2D6, mediate N-demethylation, one of the oxidative pathways for cyclobenzaprine. Cyclobenzaprine relieves skeletal muscle spasm of local origin without interfering with muscle function. Drowsiness, fatigue and sedation (up to 40%) is the most common side effect of Cyclobenzaprine. It may have life-threatening interactions with monoamine oxidase (MAO) inhibitors. Postmarketing cases of serotonin syndrome have been reported during combined use of cyclobenzaprine and other drugs such as selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tramadol, bupropion, meperidine, verapamil, or MAO inhibitors.

CNS Activity

Originator

Approval Year

1977
76
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2849
Substrate
661
Substrate
661
Substrate
661
Inhibitor
8504
 3.1 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Approved
8583
CYCLOBENZAPRINE HYDROCHLORIDE

Approved Use

Drug is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living.

Launch Date

1988
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
8.3 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/19243711
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CYCLOBENZAPRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
354.1 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/19243711
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CYCLOBENZAPRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
33.4 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/19243711
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CYCLOBENZAPRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
900 mg single, oral
Overdose
Dose: 900 mg
Route: oral
Route: single
Dose: 900 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
healthy, 18
Health Status: healthy
Age Group: 18
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
Disc. AE: Lethargy, Slurred speech...
AEs leading to
discontinuation/dose reduction:
Lethargy
Slurred speech
Sinus tachycardia
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
healthy, 24
Health Status: healthy
Age Group: 24
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
Disc. AE: Sinus tachycardia, Confusion...
AEs leading to
discontinuation/dose reduction:
Sinus tachycardia
Confusion
Drowsiness
Agitation
Visual hallucinations
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
10 mg 3 times / day multiple, oral
Recommended
Dose: 10 mg, 3 times / day
Route: oral
Route: multiple
Dose: 10 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12809957
unhealthy, 41.5
Health Status: unhealthy
Age Group: 41.5
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/12809957
Disc. AE: Somnolence...
AEs leading to
discontinuation/dose reduction:
Somnolence (5.2%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/12809957
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021777s017lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021777s017lbl.pdf
Disc. AE: Serotonin syndrome, Cardiovascular disorder NOS...
AEs leading to
discontinuation/dose reduction:
Serotonin syndrome (grade 4)
Cardiovascular disorder NOS
CNS depression
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021777s017lbl.pdf
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
Other AEs: Tachycardia, Dry mouth...
Other AEs:
Tachycardia (below serious, 1 patient)
Dry mouth (below serious, 6 patients)
Toothache (below serious, 1 patient)
Rhinitis (below serious, 1 patient)
Dizziness (below serious, 1 patient)
Dysgeusia (below serious, 1 patient)
Anxiety (below serious, 1 patient)
Disruptive mood dysregulation disorder (below serious, 1 patient)
Sleep disorder (below serious, 1 patient)
Somnolence (below serious, 18 patients)
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
AEs

AEs

AESignificanceDosePopulation
Lethargy Disc. AE
900 mg single, oral
Overdose
Dose: 900 mg
Route: oral
Route: single
Dose: 900 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
healthy, 18
Health Status: healthy
Age Group: 18
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
Sinus tachycardia Disc. AE
900 mg single, oral
Overdose
Dose: 900 mg
Route: oral
Route: single
Dose: 900 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
healthy, 18
Health Status: healthy
Age Group: 18
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
Slurred speech Disc. AE
900 mg single, oral
Overdose
Dose: 900 mg
Route: oral
Route: single
Dose: 900 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
healthy, 18
Health Status: healthy
Age Group: 18
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
Agitation Disc. AE
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
healthy, 24
Health Status: healthy
Age Group: 24
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
Confusion Disc. AE
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
healthy, 24
Health Status: healthy
Age Group: 24
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
Drowsiness Disc. AE
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
healthy, 24
Health Status: healthy
Age Group: 24
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
Sinus tachycardia Disc. AE
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
healthy, 24
Health Status: healthy
Age Group: 24
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
Visual hallucinations Disc. AE
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
healthy, 24
Health Status: healthy
Age Group: 24
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
Somnolence 5.2%
Disc. AE
10 mg 3 times / day multiple, oral
Recommended
Dose: 10 mg, 3 times / day
Route: oral
Route: multiple
Dose: 10 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12809957
unhealthy, 41.5
Health Status: unhealthy
Age Group: 41.5
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/12809957
CNS depression Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021777s017lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021777s017lbl.pdf
Cardiovascular disorder NOS Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021777s017lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021777s017lbl.pdf
Serotonin syndrome grade 4
Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021777s017lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021777s017lbl.pdf
Anxiety below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
Disruptive mood dysregulation disorder below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
Dizziness below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
Dysgeusia below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
Rhinitis below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
Sleep disorder below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
Tachycardia below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
Toothache below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
Somnolence below serious, 18 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
Dry mouth below serious, 6 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1946
substrate
1388

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1197

UGT1A4
399

UGT2B10
131
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP2D6
1388
 minor
CYP1A2
1197
 yes
CYP3A4
1946
 yes
UGT1A4
399
 yes
UGT2B10
131
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:3996
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3996
ZINC
ZINC000000968263
http://zinc15.docking.org/substances/ZINC000000968263
PubMed

PubMed

TitleDatePubMed
Pharmacokinetic profile of once-daily cyclobenzaprine extended-release.
2010-11
Efficacy and tolerability of cyclobenzaprine extended release for acute muscle spasm: a pooled analysis.
2010-07
Evidence that tricyclic small molecules may possess toll-like receptor and myeloid differentiation protein 2 activity.
2010-06-30
Pharmacologic management of chronic pain.
2010-06
Inappropriate prescribing in the hospitalized elderly patient: defining the problem, evaluation tools, and possible solutions.
2010-04-07
Menstrual-related nummular headache.
2010-04
Case files of the California poison control system, San Francisco division: blue thunder ingestion: methanol, nitromethane, and elevated creatinine.
2010-03
Antidepressant drugs in oral fluid using liquid chromatography-tandem mass spectrometry.
2010-03
Impact of poor-quality medicines in the 'developing' world.
2010-03
Comparison of ibuprofen, cyclobenzaprine or both in patients with acute cervical strain: a randomized controlled trial.
2010-01
A 19-month-old girl with recurrent illness: over the hills and through the woods.
2009-12
Patients' experiences of living with and receiving treatment for fibromyalgia syndrome: a qualitative study.
2009-10-07
Electroencephalographic correlates of Chronic Fatigue Syndrome.
2009-10-06
Drugs associated with more suicidal ideations are also associated with more suicide attempts.
2009-10-02
Fibromyalgia and myofascial pain syndrome-a dilemma.
2009-10
Plasmapheresis in a patient with rhabdomyolysis: a case report.
2009-08-12
Methemoglobinemia: life-threatening hazard of multiple drug ingestions.
2009-07-18
Cyclobenzaprine for the treatment of myofascial pain in adults.
2009-07-08
Standardized natural product cannabis in pain management and observations at a Canadian compassion society: a case report.
2009-05-18
Is there sufficient evidence to suggest cyclobenzaprine might be implicated in causing serotonin toxicity?
2009-05
Cyclobenzaprine ER for muscle spasm associated with low back and neck pain: two randomized, double-blind, placebo-controlled studies of identical design.
2009-05
Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse/toxicology screening in emergency medicine.
2009-04-28
Bioavailability of a controlled-release cyclobenzaprine tablet and influence of a high fat meal on bioavailability.
2009-04
Rhabdomyolysis associated with the nutritional supplement Hydroxycut.
2009-01-15
A pharmacokinetic comparison of single doses of once-daily cyclobenzaprine extended-release 15 mg and 30 mg: a randomized, double-blind, two-period crossover study in healthy volunteers.
2009-01
Insights in to the pathogenesis of axial spondyloarthropathy based on gene expression profiles.
2009
Torticollis under cyclobenzaprine.
2009
Effects of naltrexone on pain sensitivity and mood in fibromyalgia: no evidence for endogenous opioid pathophysiology.
2009
Effect of food on the pharmacokinetics of once-daily cyclobenzaprine extended-release 30 mg: a randomized, open-label, crossover, single-centre study.
2009
Comparison of the single-dose pharmacokinetics of once-daily cyclobenzaprine extended-release 30 mg and cyclobenzaprine immediate-release 10 mg three times daily in the elderly: a randomized, open-label, crossover study.
2009
Treatment options and patient perspectives in the management of fibromyalgia: future trends.
2008-12
Newer treatments for fibromyalgia syndrome.
2008-12
Anticholinergic esotropia.
2008-12
A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia.
2008-11-30
Elderly patient refractory to multiple pain medications successfully treated with integrative East-West medicine.
2008-11-30
Bertolotti's syndrome: a case report.
2008-11-29
Leiomyosarcoma of the breast in a patient with a 10-year-history of cyclophosphamide exposure: a case report.
2008-11-07
Lower facial contouring with botulinum toxin type A.
2008-11
Serotonin syndrome in a patient taking Lexapro and Flexeril: a case report.
2008-11
Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews.
2008-10-25
Neuralgic amyotrophy associated with antibiotic therapy.
2008-09
Choosing a skeletal muscle relaxant.
2008-08-01
Rasagiline in treatment of Parkinson's disease.
2008-02
Skeletal muscle relaxants.
2008-02
Endoscopic findings in loin pain hematuria syndrome: concentric clot in calyceal fornices.
2008
Single-dose pharmacokinetics of once-daily cyclobenzaprine extended release 30 mg versus cyclobenzaprine immediate release 10 mg three times daily in healthy young adults : a randomized, open-label, two-period crossover, single-centre study.
2008
A meta-analysis of the efficacy of fibromyalgia treatment according to level of care.
2008
Cost-utility of an 8-month aquatic training for women with fibromyalgia: a randomized controlled trial.
2008
Extended-release cyclobenzaprine (Amrix).
2007-12-17
Antidepressants in the treatment of fibromyalgia.
2006-12
Patents

Patents

GB858187
2
JP2006505569A
69
JP4763957B2
87

Sample Use Guides

In Vivo Use Guide
5 mg three times a day. Based on individual patient response, the dose may be increased to either 7.5 mg or 10 mg three times a day.
Route of Administration: Oral
In Vitro Use Guide
The iontaphoretic application of Cyclobenzaprine (CBZ) caused, in all cases, a decrease in discharge rate. This slowing was invariably attended by a marked decrease in action potential amplitude however, and was therefore considered likely to be a local anesthetic effect, even at 5 nA. On the other hand, when CBZ was infused into the chamber to a concentration equivalent to 1 mg/kg for the whole animal, assuming distribution in all extracellular water, all cells responded and no local anesthetic effects were evident. The six cells with initial discharge rates between 2 and 10 Hz decreased firing with CBZ, whereas the four cells with initial rates between 0.5 and 1.5 Hz increased their rates with CBZ.
Substance Class Chemical
Created
by admin
on Wed Apr 02 07:35:22 GMT 2025
Edited
by admin
on Wed Apr 02 07:35:22 GMT 2025
Record UNII
69O5WQQ5TI
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MK-130 (AS THE BASE)
Preferred Name English
CYCLOBENZAPRINE
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
CYCLOBENZAPRINE [MI]
Common Name English
Cyclobenzaprine [WHO-DD]
Common Name English
MK-130
Systematic Name English
cyclobenzaprine [INN]
Common Name English
CYCLOBENZAPRINE [VANDF]
Common Name English
CYCLOBENZAPRINE [USP IMPURITY]
Common Name English
N,N-DIMETHYL-5H-DIBENZO(A,D)CYCLOHEPTENE-(SUP .DELTA.5,.GAMMA.)-PROPYLAMINE
Common Name English
TNX-102
Code English
AMITRIPTYLINE HYDROCHLORIDE IMPURITY B [EP IMPURITY]
Common Name English
NORTRIPTYLINE HYDROCHLORIDE IMPURITY E [EP IMPURITY]
Common Name English
1-PROPANAMINE, 3-(5H-DIBENZO(A,D)CYCLOHEPTEN-5-YLIDENE)-N,N-DIMETHYL-
Systematic Name English
3-(5H-DIBENZO(A,D)(7)ANNULEN-5-YLIDENE)-N,N-DIMETHYLPROPAN-1-AMINE
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C29696
Created by admin on Wed Apr 02 07:35:22 GMT 2025 , Edited by admin on Wed Apr 02 07:35:22 GMT 2025
NDF-RT N0000175737
Created by admin on Wed Apr 02 07:35:22 GMT 2025 , Edited by admin on Wed Apr 02 07:35:22 GMT 2025
NDF-RT N0000175730
Created by admin on Wed Apr 02 07:35:22 GMT 2025 , Edited by admin on Wed Apr 02 07:35:22 GMT 2025
WHO-VATC QM03BX08
Created by admin on Wed Apr 02 07:35:22 GMT 2025 , Edited by admin on Wed Apr 02 07:35:22 GMT 2025
LIVERTOX NBK548894
Created by admin on Wed Apr 02 07:35:22 GMT 2025 , Edited by admin on Wed Apr 02 07:35:22 GMT 2025
WHO-ATC M03BX08
Created by admin on Wed Apr 02 07:35:22 GMT 2025 , Edited by admin on Wed Apr 02 07:35:22 GMT 2025
Code System Code Type Description
LACTMED
Cyclobenzaprine
Created by admin on Wed Apr 02 07:35:22 GMT 2025 , Edited by admin on Wed Apr 02 07:35:22 GMT 2025
PRIMARY
EVMPD
SUB06849MIG
Created by admin on Wed Apr 02 07:35:22 GMT 2025 , Edited by admin on Wed Apr 02 07:35:22 GMT 2025
PRIMARY
FDA UNII
69O5WQQ5TI
Created by admin on Wed Apr 02 07:35:22 GMT 2025 , Edited by admin on Wed Apr 02 07:35:22 GMT 2025
PRIMARY
DRUG CENTRAL
751
Created by admin on Wed Apr 02 07:35:22 GMT 2025 , Edited by admin on Wed Apr 02 07:35:22 GMT 2025
PRIMARY
WIKIPEDIA
CYCLOBENZAPRINE
Created by admin on Wed Apr 02 07:35:22 GMT 2025 , Edited by admin on Wed Apr 02 07:35:22 GMT 2025
PRIMARY
ECHA (EC/EINECS)
206-145-8
Created by admin on Wed Apr 02 07:35:22 GMT 2025 , Edited by admin on Wed Apr 02 07:35:22 GMT 2025
PRIMARY
ChEMBL
CHEMBL669
Created by admin on Wed Apr 02 07:35:22 GMT 2025 , Edited by admin on Wed Apr 02 07:35:22 GMT 2025
PRIMARY
MERCK INDEX
m3976
Created by admin on Wed Apr 02 07:35:22 GMT 2025 , Edited by admin on Wed Apr 02 07:35:22 GMT 2025
PRIMARY Merck Index
IUPHAR
7152
Created by admin on Wed Apr 02 07:35:22 GMT 2025 , Edited by admin on Wed Apr 02 07:35:22 GMT 2025
PRIMARY
SMS_ID
100000083730
Created by admin on Wed Apr 02 07:35:22 GMT 2025 , Edited by admin on Wed Apr 02 07:35:22 GMT 2025
PRIMARY
DRUG BANK
DB00924
Created by admin on Wed Apr 02 07:35:22 GMT 2025 , Edited by admin on Wed Apr 02 07:35:22 GMT 2025
PRIMARY
CAS
303-53-7
Created by admin on Wed Apr 02 07:35:22 GMT 2025 , Edited by admin on Wed Apr 02 07:35:22 GMT 2025
PRIMARY
HSDB
8305
Created by admin on Wed Apr 02 07:35:22 GMT 2025 , Edited by admin on Wed Apr 02 07:35:22 GMT 2025
PRIMARY
INN
791
Created by admin on Wed Apr 02 07:35:22 GMT 2025 , Edited by admin on Wed Apr 02 07:35:22 GMT 2025
PRIMARY
MESH
C004704
Created by admin on Wed Apr 02 07:35:22 GMT 2025 , Edited by admin on Wed Apr 02 07:35:22 GMT 2025
PRIMARY
NCI_THESAURUS
C28947
Created by admin on Wed Apr 02 07:35:22 GMT 2025 , Edited by admin on Wed Apr 02 07:35:22 GMT 2025
PRIMARY
CHEBI
3996
Created by admin on Wed Apr 02 07:35:22 GMT 2025 , Edited by admin on Wed Apr 02 07:35:22 GMT 2025
PRIMARY
DAILYMED
69O5WQQ5TI
Created by admin on Wed Apr 02 07:35:22 GMT 2025 , Edited by admin on Wed Apr 02 07:35:22 GMT 2025
PRIMARY
RXCUI
21949
Created by admin on Wed Apr 02 07:35:22 GMT 2025 , Edited by admin on Wed Apr 02 07:35:22 GMT 2025
PRIMARY RxNorm
PUBCHEM
2895
Created by admin on Wed Apr 02 07:35:22 GMT 2025 , Edited by admin on Wed Apr 02 07:35:22 GMT 2025
PRIMARY
EPA CompTox
DTXSID0046933
Created by admin on Wed Apr 02 07:35:22 GMT 2025 , Edited by admin on Wed Apr 02 07:35:22 GMT 2025
PRIMARY
Related Record Type Details
Structure of CYCLOBENZAPRINE HYDROCHLORIDE
SALT/SOLVATE -> PARENT
ALDEHYDE OXIDASE
METABOLIC ENZYME -> INHIBITOR
IC50
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
CYTOCHROME P450 1A2
METABOLIC ENZYME -> SUBSTRATE
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A4
METABOLIC ENZYME -> SUBSTRATE
5-HYDROXYTRYPTAMINE RECEPTOR 2A
TARGET -> INHIBITOR
Related Record Type Details
Structure of CYCLOBENZAPRINE N-GLUCURONIDE
METABOLITE -> PARENT
Structure of 3-HYDROXYCYCLOBENZAPRINE
METABOLITE -> PARENT
Structure of CYCLOBENZAPRINE EPOXIDE
METABOLITE -> PARENT
Structure of 2-HYDROXYCYCLOBENZAPRINE
METABOLITE -> PARENT
Structure of NORCYCLOBENZAPRINE
METABOLITE -> PARENT
MAJOR
Structure of CYCLOBENZAPRINE N-GLUCURONIDE
METABOLITE -> PARENT
Structure of CYCLOBENZAPRINE N-OXIDE
METABOLITE -> PARENT
Related Record Type Details
Structure of AMITRIPTYLINE HYDROCHLORIDE
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of AMITRIPTYLINE HYDROCHLORIDE
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of Nortriptyline Hydrochloride
PARENT -> IMPURITY
Related Record Type Details
Structure of CYCLOBENZAPRINE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Route of Elimination PHARMACOKINETIC EXCRETED UNCHANGED, RENAL
PHARMACOKINETIC
PROTEIN BINDING PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC ORAL, EXTENDED-RELEASE
PHARMACOKINETIC
ORAL, EXTENDED-RELEASE (ELDERLY OLDER THAN 65 YEARS)
PHARMACOKINETIC
ORAL BIOAVAILABILITY PHARMACOKINETIC
Tmax PHARMACOKINETIC ORAL, EXTENDED-RELEASE CAPSULE (15 mg DOSE)
PHARMACOKINETIC
ORAL, EXTENDED-RELEASE CAPSULE (30 mg DOSE)
PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966